Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.
Ultra-sensitive blood tests identify triple-negative breast cancer patients at highest risk after treatment, guiding who needs closer monitoring or intensified therapy.
Ultrasensitive ctDNA detection post-neoadjuvant therapy significantly improved prognostication in TNBC, identifying high-risk patients beyond pathological complete response assessment, which represents the current standard prognostic tool. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective diagnostic/prognostic cohort study (ESMO Open, multicenter French)
- Category
- early_cancer_detection
- Maturity
- Potentially Practice-Changing
- Journal
- ESMO Open
Why it surfaced
TNBC is the subtype with highest relapse risk and least established prognostic biomarkers post-neoadjuvant therapy. ctDNA-based prognostication in this setting has direct clinical utility for treatment stratification and adjuvant therapy decisions (e.g., capecitabine, olaparib, pembrolizumab decisions).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.